

Figure 4. Despite classification as CR by CT and ultrasonography, residual invasive components remained in the specimen by histologic examination. (a) The localized tumor measured 7.5 cm × 3.5 cm in diameter. (b) After NAC, no enhanced lesions were observed by CT. Only a low-echoic area, as low as fat tissue, could be observed by ultrasonography. (c) Invasive components could still be observed histologically.

Acknowledgments

This study was supported in part by a grant-in-aid for cancer research from the Ministry of Health, Labor and Welfare, and a Health and Labor Sciences research grant for research on advanced medical technology (toxicogenomics), Japan.

REFERENCES

1. Buzdar AU, Hunt K, Smith T, *et al.* Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. *J Clin Oncol* 2004;22(July 15 Suppl):520. Abstract.

2. Akashi-Tanaka S, Fukutomi T, Watanabe T, *et al.* Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. *Int J Cancer* 2001;96:66–73.

3. Rosen EL, Blackwell KL, Baker JA, *et al.* Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. *Am J Roentgenol* 2003;181:1275–82.

4. Cheung YC, Chen SC, Su MY, *et al.* Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. *Breast Cancer Res Treat* 2003;78:51–58.

5. Ogawa Y, Nishioka A, Kubota K, *et al.* CT findings of breast cancer with clinically complete response following neoadjuvant chemotherapy—histological correlation. *Oncol Rep* 2003;10:1411–15.

6. Mumtaz H, Davidson T, Spittle M, *et al.* Breast surgery after neoadjuvant treatment. Is it necessary? *Eur J Surg Oncol* 1996;22:335–41.

7. Therasse P, Arbuck SG, Eisenhauer EA, *et al.* New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* 2000;92:205–16.

8. Akashi-Tanaka S, Fukutomi T, Sato N, *et al.* The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. *Ann Surg* 2004;239:238–43.

9. Akashi-Tanaka S, Fukutomi T, Miyakawa K, Uchiyama N, Tsuda H. Diagnostic value of contrast-enhanced computed tomography for diagnosing the intraductal component of breast cancer. *Breast Cancer Res Treat* 1998;49:79–86.

10. Akashi-Tanaka S, Watanabe T, Fukutomi T, *et al.* Diagnosis of residual breast cancer after neoadjuvant at chemotherapy using contrast-enhanced computed tomography. *J Clin Oncol* 2001;20(May 12 Suppl):1829. Abstract.

11. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A. Effect of preoperative chemotherapy on the outcome of women with operative breast cancer. *J Clin Oncol* 1998;16:2672–85.

12. Ring A, Webb A, Ashley S, *et al.* Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? *J Clin Oncol* 2003;21:4540–45.

13. Esserman L, Kaplan E, Partridge S, *et al.* MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. *Ann Surg Oncol* 2001;8:549–59.

Excerpta Medica

The American Journal of Surgery

The American Journal of Surgery 191 (2006) 225–229
Scientific papers–International

Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy

Takayuki Kinoshita, M.D.[a,*], Miyuki Takasugi, M.D.[a], Eriko Iwamoto, M.D.[a], Sadako Akashi-Tanaka, M.D.[a], Takashi Fukutomi, M.D.[a], Shoji Terui, M.D.[b]

[a]*Division of Surgical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan*
[b]*Division of Nuclear Medicine, National Cancer Center Hospital, Tsukiji Chuo-ku, Tokyo, Japan*

Manuscript received February 10, 2005; revised manuscript June 22, 2005

Abstract

Background: The feasibility and accuracy of sentinel lymph node (SLN) biopsy examination for breast cancer patients with clinically node-negative breast cancer after neoadjuvant chemotherapy (NAC) have been investigated under the administration of a radiocolloid imaging agent injected intradermally over a tumor. In addition, conditions that may affect SLN biopsy detection and false-negative rates with respect to clinical tumor response and clinical nodal status before NAC were analyzed.

Methods: Seventy-seven patients with stages II and III breast cancer previously treated with NAC were enrolled in the study. All patients were clinically node negative after NAC. The patients then underwent SLN biopsy examination, which involved a combination of intradermal injection over the tumor of radiocolloid and a subareolar injection of blue dye. This was followed by standard level I/II axillary lymph node dissection.

Results: The SLN could be identified in 72 of 77 patients (identification rate, 93.5%). In 69 of 72 patients (95.8%) the SLN accurately predicted the axillary status. Three patients had a false-negative SLN biopsy examination result, resulting in a false-negative rate of 11.1% (3 of 27). The SLN identification rate tended to be higher, although not statistically significantly, among patients who had clinically negative axillary lymph nodes before NAC (97.6%; 41 of 42). This is in comparison with patients who had a positive axillary lymph node before NAC (88.6%; 31 of 35).

Conclusions: The SLN identification rate and false-negative rate were similar to those in nonneoadjuvant studies. The SLN biopsy examination accurately predicted metastatic disease in the axilla of patients with tumor response after NAC and clinical nodal status before NAC. This diagnostic technique, using an intradermal injection of radiocolloid, may provide treatment guidance for patients after NAC.

Keywords: Sentinel node biopsy; Neoadjuvant chemotherapy; Clinically node negative; Intradermal injection

Currently, the status of the axillary lymph nodes remains the most important prognostic indicator for breast cancer and helps the physician in guiding adjuvant therapy. More than 40 peer-reviewed pilot studies published between 1993 and 1999 have established the validity of sentinel lymph node (SLN) biopsy examination technique for clinically node-negative breast cancer [1], and the SLN biopsy procedure has become the standard of care for axillary staging in these patients.

Recent studies report identification rates of more than 90%, with false-negative rates ranging from 2% to 10% [2,3]. To ensure a high SLN identification rate and a low false-negative rate, some relative contraindications for SLN biopsy examination have been established: these include T3 or T4 tumors, multicentric or multifocal lesions, a large biopsy cavity, previous axillary surgery, previous chest-wall irradiation, and neoadjuvant chemotherapy (NAC) [4,5].

The application of SLN biopsy examination in NAC-treated patients may, as in nonneoadjuvant chemotherapy groups, identify patients who do not necessarily require an axillary lymph node dissection (ALND). Several studies

* Corresponding author. Tel.: +81-3-3542-2511; fax: +81-3-3542-3815.
E-mail address: takinosh@ncc.go.jp

0002-9610/06/$ – see front matter
doi:10.1016/j.amjsurg.2005.06.049

Table 1
Patient demographics

	Number of patients
Age, y	
Mean	51.1
Range	27–75
Clinical tumor size, cm*	
Mean	4.82
Range	2.7–12
Tumor classification*	
T2	50 (65.0%)
T3	24 (31.2%)
T4	3 (3.8%)
Lymph node status*	
N0	42 (54.5%)
N1	28 (36.4%)
N2	7 (9.1%)
Tumor type	
Invasive ductal	74 (96.1%)
Invasive lobular	3 (3.9%)
Type of NAC	
FEC plus paclitaxel	73 (94.9%)
Paclitaxel alone	4 (5.1%)
Clinical response of the tumor	
CR	41 (53.2%)
PR	28 (36.4%)
SD	8 (10.4%)
Pathologic response of the tumor	
pCR	17 (22.1%)
pINV	60 (77.9%)
Pathologic nodal status	
Negative	47 (61.0%)
Positive	30 (39.0%)

CR = complete response; FEC = fluorouracil/epirubicin/cyclophosphamide; PR = partial response; SD = stable disease; pCR = pathologic complete response; pINV = pathologic invasive.
* Before NAC.

have evaluated the use of SLN biopsy examination in patients with breast cancer after NAC but results are varied and inconclusive [6–14].

Recently, several studies have shown the feasibility and accuracy of SLN biopsy examination using peritumoral injection of radiocolloid for patients with NAC-treated breast cancer. However, false-negative rates varied considerably among these studies [6–13]. It is possible that tumor response to chemotherapy may alter or interrupt the lymphatic drainage, thus causing the lower SLN identification rates and higher false-negative rates as opposed to nonneoadjuvant studies. Our hypothesis is that the lymphatic flow within the skin lesion overlying the tumor is less damaged by the chemotherapy than that in the parenchyma surrounding the tumor, except in T4 tumors. Thus, the usefulness of SLN biopsy examination with intradermal injection of radiocolloid for patients with NAC-treated breast cancer has yet to be established.

The aim of this study was to determine the feasibility and accuracy of the SLN biopsy procedure using intradermal injection of radiocolloid over the tumor in clinically node-negative NAC-treated breast cancer patients.

Methods

Between May 2003 and January 2005, 77 patients with T2-4N0-2 breast cancer underwent NAC with SLN biopsy examination plus ALND performed by a single surgeon. The pathologic diagnosis was established by core needle biopsy examination in all patients.

Patients younger than 65 years of age received 4 cycles of 5-fluorouracil (500 mg/m^2)/epirubicin (100 mg/m^2)/cyclophosphamide (500 mg/m^2) plus 12 weekly cycles of paclitaxel (80 mg/m^2), and patients older than 65 years of age received 12 weekly cycles of paclitaxel (80 mg/m^2) alone. After NAC, we enrolled the 77 clinically node-negative patients in this study.

Lymphatic mapping was performed using a 3-mL combination of blue dye (Patent blue V; TOC Ltd, Tokyo, Japan) and 30 to 80 MBq of technetium-99m–labeled Phytate (Daiichi RI Laboratory, Ltd, Tokyo, Japan). The day before surgery, the radiotracer was injected intradermally into the area overlying the tumor, and blue dye was injected into the subareolar site intraoperatively. For nonpalpable lesions, injections were performed under mammographic or ultrasonic needle localization. Sentinel lymph nodes were identified as being stained blue, radioactive, or both. The SLN biopsy procedure then was followed by a standard level I/II ALND.

All sentinel nodes were evaluated histologically by submitting each node as a 3-mm to 5-mm serial section stained with hematoxylin-eosin. Lymph nodes submitted as part of the axillary dissection were totally submitted and evaluated using standard hematoxylin-eosin staining.

Results

Patient characteristics, type of chemotherapy, clinical response of the tumor, and pathologic findings are summarized in Table 1. All patients underwent breast-conserving therapy or mastectomy and were clinically node negative at the time of surgery.

As shown in Table 2, the overall SLN identification rate was 93.5% (72 of 77). Of the 72 patients in whom an SLN could be identified, 24 (33.3%) had positive SLNs. Within

Table 2
Results of sentinel node biopsy examination

	Number of patients
Total number of patients	77
SLN identified	72 (93.5%)
SLN positive	24 (33.3%)
SLN was only positive lymph node	11 (45.8%)
SLN identification method	
Radiocolloid and blue dye	53 (73.6%)
Radiocolloid only	11 (14.3%)
Blue dye only	8 (11.1%)

Table 3
Comparison of lymph node status of SLNs and non-SLNs

SLN status	Non-SLN status	
	Positive	Negative
Positive	13	11
Negative	3	45

False-negative rate = 11.1%.

11 of these patients (45.8%), the SLN was the only positive node. SLNs were identified by both radiocolloid and blue dye in 53 patients (73.6%), by radiocolloid alone in 11 patients (14.3%), and by blue dye alone in 8 patients (11.1%).

The pathologic status of the SLNs and non SLNs is shown in Table 3.

The SLNs accurately predicted the axillary status in 69 of 72 patients (95.8%). Three patients had a false-negative SLN biopsy examination result, resulting in a false-negative rate of 11.1% (3 of 27). Forty-five patients had pathologically negative SLNs and non-SLNs.

The pathologic status of the SLNs and non-SLNs were analyzed according to tumor classifications before NAC, clinical lymph node status before NAC, and response of the tumor after NAC, respectively.

In T2 tumors before NAC, the SLN identification rate was 94% (47 of 50), and 2 patients had a false-negative SLN biopsy examination result, resulting in a false-negative rate of 14.3%. In T3 and T4 tumors, results were 92.6% (25 of 27) and 7.7% (2 of 27), respectively (Table 4). For the results of SLN biopsy examination, there was no significant difference between T2 and T3/T4 tumors before NAC.

In the patients with clinically negative lymph nodes (N0) before NAC, the SLN identification rate was 97.6% (41 of 42), and 1 patient had a false-negative SLN biopsy examination result, resulting in a false-negative rate of 10%. In the patients with clinically positive lymph nodes (N1/N2), the results were 88.6% (31 of 35) and 11.2% (4 of 35), respectively (Table 5). The SLN identification rate tended to be higher, although not statistically significantly, among patients who had clinically negative lymph nodes before NAC compared with patients who had positive axillary lymph nodes before NAC.

Table 4
Comparison of lymph node status of SLNs and non-SLNs among tumor classifications before NAC

SLN status	Non-SLN status			
	T2 (n = 50)		T3/T4 (n = 27)	
	Positive	Negative	Positive	Negative
Positive	6	6	7	5
Negative	2	33	1	12
Total number of SLNs identified	47 (94%)		25 (92.6%)	
False-negative rate	14.3%		7.7%	

Table 5
Comparison of lymph node status of SLNs and non-SLNs among nodal status before NAC

SLN status	Non-SLN status			
	N0 (n = 42)		N1/N2 (n = 35)	
	Positive	Negative	Positive	Negative
Positive	3	6	10	5
Negative	1	31	2	14
Total number of SLNs identified	41 (97.6%)		31 (88.6%)	
False-negative rate	10%		11.2%	

For patients with complete tumor response after NAC, the SLN identification rate was 92.0% (37 of 41), with 1 patient having a false-negative SLN biopsy examination result, resulting in a false-negative rate of 12.5%. For patients with a partial tumor response and stable disease, the results were 97.2% (35 of 36) and 10.5% (1 of 36), respectively (Table 6). The SLN identification rate tended to be lower, although not statistically significantly, among patients with complete tumor response after NAC, compared with partial tumor response and patients with stable disease after NAC.

There was no significant difference in the false-negative rate according to tumor classifications before NAC, clinical lymph node status before NAC, and response of the tumor after NAC.

Comments

ALND is the surgical standard for treatment of the axilla in breast cancer patients. The rationales for ALND are exact staging and prognosis, regional control of the axilla, and the possibility of improved survival. The extent of axillary lymph node involvement is one of the most important independent prognostic factors for recurrence and survival. The SLN biopsy procedure is an accurate minimally invasive method for axillary staging in early breast cancers. In many clinics the SLN biopsy examination is replacing standard ALND because of minimal morbidity. However, with the increasing size of tumors, lymphatic mapping becomes

Table 6
Comparison of lymph node status of SLNs and non-SLNs among clinical response after NAC

SLN status	Non-SLN status			
	CR (n = 41)		PR/SD (n = 36)	
	Positive	Negative	Positive	Negative
Positive	3	4	10	7
Negative	1	29	2	16
Total number of SLNs identified	37 (90.2%)		35 (97.2%)	
False-negative rate	12.5%		10.5%	

Table 7
Studies of SLN biopsy procedures after NAC

	Number of patients	Stage	Tumor size, cm	Number (%) of successful SLN biopsy procedures	False negative (%)
Breslin et al [6], 2000	51	II or III	5.0	43 (84.3)	3 (12)
Miller et al [7], 2002	35	T1-3N0	3.5	30 (86.0)	0 (0)
Stearns et al [8], 2000	34	T3-4, any N	5.0	29 (85.0)	3 (14)
Haid et al [9], 2001	33	T1-3, any N	3.3	29 (88.0)	0 (0)
Julian et al [11], 2002	31	I or II	NS	29 (93.5)	0 (0)
Tafra et al [12], 2001	29	Any T, N0	NS	27 (93.0)	0 (0)
Nason et al [13], 2000	15	T2-4, N0	NS	13 (87.0)	3 (33)
Shimazu et al [14], 2004	47	II or III	4.5	44 (93.6)	4 (12)
Current study	77	T2-4, any N	4.8	72 (93.5)	3 (11)

NS = not specified.

less accurate [15,16]. NAC can reduce tumor size and significantly increase the ability to perform breast-conserving therapy [17,18]. After NAC, axillary downstaging is affected similarly. NAC with anthracycline/cyclophosphamide-containing regimens has been shown to neutralize involved axillary nodes in about 30% of patients [17]. The addition of taxanes to anthracycline/cyclophosphamide-containing regimens has increased the conversion rate to around 40% [19,20]. With the increasing number of patients receiving NAC, the question arises of whether the SLN biopsy examination is an option for these patients. We summarized the studies concerning SLN biopsy examination after NAC in Table 7, but they are inconclusive [6–14]. Breslin et al [6] reported a study of 51 patients who underwent an SLN biopsy examination after NAC and concluded that an SLN biopsy examination is accurate after NAC. They had an identification rate of 84.3% and a false-negative rate of 12.0%. Nason et al [13] reported on a smaller number of patients who received NAC. Their identification rate was 87.0% and their false-negative rate was 33.3%, concluding that the SLN biopsy examination resulted in an unacceptably high false-positive rate. We have to understand that in most of these small series, even 1 or 2 patients with a false-negative SLN node can sway the conclusions in a different direction. We report a study of 77 patients who received NAC, and had an identification rate of 93.5% and a false-negative rate of 11.1%. We conclude in our study that an SLN biopsy examination after NAC is accurate even for large tumors and positive axillary nodal status before NAC without inflammatory breast cancer.

It has been speculated that among patients who have their axillary lymph node status downstaged by NAC, tumors also typically respond to NAC and shrink, so that damage to and alteration of the lymphatic flow from tumor tissues to the axillary basin are more likely to occur. This may cause an increase in the false-negative rate for SLN biopsy examination and a decreasing identification rate for SLN biopsy examination. Our hypothesis is that the lymphatic flow around the skin lesion is rich and less influenced by the effect of chemotherapy and tumor size than that in the parenchyma around the tumor. Our results were not significantly influenced by tumor size, tumor response, or nodal status before NAC.

In conclusion, the results of our study suggest that an SLN biopsy procedure after NAC using intradermal injection of radiocolloid is feasible and can predict axillary lymph node status with high accuracy for patients with clinically negative lymph node status after NAC. This procedure could make patients who have had their axillary lymph node status downstaged from positive to negative and patients with large tumors appropriate candidates for an SLN biopsy examination.

Further studies involving a larger number of patients will be required to establish fully the feasibility and accuracy of the SLN biopsy procedure for patients with breast cancer who have been treated with NAC.

References

[1] Cody HS 3rd. Clinical aspects of sentinel node biopsy. Breast Cancer Res 2001;3:104–8.
[2] Cody HS, Borgen PI. State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique and quality control at Memorial Sloan-Kettering Cancer Center. Surg Oncol 1999;8:85–91.
[3] Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339:941–6.
[4] Anderson BO. Sentinel lymphadenectomy in breast cancer: an update on NCCN Clinical Practice Guidelines. J Natl Compr Cancer Network 2003;1(Suppl 1):S64–70.
[5] Reintgen D, Giuliano R, Cox C. Lymphatic mapping and sentinel lymph node biopsy for breast cancer. Cancer J 2002;8(Suppl 1):S15–21.
[6] Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy in accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480–6.
[7] Miller AR, Thompson VE, Yeh IT, et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002;9:243–7.
[8] Stearns V, Ewing CA, Slake R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliable represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2000;9:235–42.

[9] Haid A, Tausch C, Lang A, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast cancer? Cancer 2001;92:1080–4.
[10] Julian TB, Patel N, Dusi D, et al. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001;182:407–10.
[11] Julian TB, Dusi D, Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2002;184:315–7.
[12] Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 2001;182:312–5.
[13] Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187–94.
[14] Shimazu K, Tamaki Y, Taguchi T, et al. Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer 2004;100:2555–61.
[15] Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000;88:2540–5.
[16] O'Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423–7.
[17] Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–93.
[18] Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456–66.
[19] Mamounaus E, Brown A, Smith R, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: update results from NSABP B-27. Proc Am Soc Clin Oncol 2002;21:36a.
[20] Gianni L, Baselga H, Eiermann W, et al. First report of European Cooperative Trial in operable breast cancer (ECTO): effect of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 2002;21:34a.

Breast Cancer
Vol. 13 No. 1 January 2006

Case Report

A Case of Mucinous Carcinoma of the Breast that Demonstrated a Good Pathological Response to Neoadjuvant Chemotherapy Despite a Poor Clinical Response

Junpei Yamaguchi, Sadako Akashi-Tanaka, Takashi Fukutomi, Takayuki Kinosita, Eriko Iwamoto, and Miyuki Takasugi

Breast Surgery Division, National Cancer Center Hospital, Japan.

A 30-year-old woman presented with a right breast tumor. Mucinous carcinoma was diagnosed by core needle biopsy (T2: 5 cm N1 M0). Despite receiving a neoadjuvant anthracycline and taxane regimen, the patient demonstrated no clinical response (NC). Based on the patient's strong preference, we performed breast-conserving surgery. On histological examination, we observed widespread mucus and a few viable malignant cells, a Grade 2 therapeutic response. Neither optimal management procedures nor guidelines for chemotherapy for primary mucinous carcinoma of the breast have been established. It is a reasonable assumption, however, that discordance between the clinical response and therapeutic response to neoadjuvant chemotherapy may occur in cases of mucinous carcinoma.

Breast Cancer 13:100-103, 2006.

Key words: Breast cancer, Mucinous carcinoma, Therapeutic response, Neoadjuvant chemotherapy

Neoadjuvant chemotherapy results in significant regression of primary breast carcinomas, thus allowing breast-conserving surgery. While a variety of imaging modalities are useful to estimate the extent of residual tumor[1,2], chemotherapy-induced fibrosis, tumor necrosis, and remaining fibrocystic changes make it difficult to evaluate the residual tumor load accurately. As far as we know, no reports have evaluated the responses to chemotherapy and neoadjuvant chemotherapy of mucinous carcinoma of the breast. In this report, we describe a case of breast mucinous carcinoma that demonstrated a pathological Grade 2 response, according to the histopathological response criteria of the Japanese Breast Cancer Society[3], despite a poor clinical response to neoadjuvant chemotherapy.

Case Report

A 30-year-old premenopausal woman was referred to our hospital with a lump in her breast. Physical examination revealed a hard elastic mass measuring 5 × 4.5 cm in diameter located in the upper outer quadrant of her right breast. An enlarged lymph node was also palpable in the right axilla. Mammography (MMG) displayed a well-circumscribed and high-density tumor shadow with microcalcifications (Fig 1A). The tumor measured approximately 5 cm in diameter by MMG. Ultrasonography (US) revealed an irregularly shaped hypoechoic lesion in the right breast, measuring over 5 cm in diameter (Fig 1B). The swollen lymph node was 1.5 cm in diameter, which was highly suggestive of lymph node metastasis. Serum levels of multiple tumor markers were normal; CEA levels were 2.0 ng/ml (normal: <5.0), CA15-3 was 6 U/ml (nl: <28), and ST439 was <1.0 U/ml (nl: <7.0). A core needle biopsy revealed mucinous carcinoma. Immunohistochemical analysis revealed no reactivity for either Estrogen receptor (ER) or Progesterone receptor (PgR). We did not observe immunoreactivity for p-53 or c-erbB-2 overexpression in this tumor.

The patient received neoadjuvant chemotherapy consisting of four cycles of 5FU (500 mg/m^2), epirubicin (100 mg/m^2), and cyclophosphamide (500 mg/m^2) every three weeks, followed by 12 cycles of paclitaxel (80 mg/m^2) weekly. The che-

Reprint requests to Junpei Yamaguchi, Breast Surgery Division, National Cancer Center Hospital, 5-1-1 Tukiji, Chuo-ku, Tokyo 104-0045, Japan.

Received January 7, 2005; accepted July 27, 2005



Fig 1. Mammography (MMG) showed a well-circumscribed, high-density tumor shadow with microcalcifications (A), while ultrasonography (US) revealed an irregularly shaped hypoechoic lesion in the right breast, measuring over 5 cm in diameter (B).



Fig 2. Additional imaging modalities (MMG (A) and US (B)) also revealed a tumor with similar size and features to that observed prior to the chemotherapy.

motherapeutic course was completed and the toxicities were tolerable. After the termination of chemotherapy, however, the tumor size remained unchanged. The tumor measured 4.5 × 4 cm in diameter by palpation, and the axillary lymph node was still palpable. The imaging examinations (MMG and US) also revealed a tumor of the same size with similar features as those seen prior to chemotherapy (Fig 2). Contrast-enhanced computed tomography (CE-CT) of the breast revealed an irregularly shaped faintly enhanced tumor shadow approximately 5 cm in diameter (Fig 3). Considering these features, we evaluated the clinical



Fig 3. Contrast-enhanced computed tomography (CE-CT) of the breast revealed an irregularly shaped tumor shadow, which faintly enhanced and measured about 5 cm in diameter.

response to chemotherapy as no change (NC).

According to the patient's preference, we performed a wide resection of the tumor in the right breast with a level II lymph node dissection (Bp+Ax). The cut margin of the specimen was negative (free margin: 2 cm). Histologically, the tumor exhibited a pure infiltrating mucinous carcinoma, with no infiltrating ductal carcinoma component. The pathological tumor size was 5.0 cm in diameter and histological cut margin was also negative. Despite widespread mucus in the breast tumor, we recognized only a few viable malignant cells. The majority of the remaining tumor cells were necrotic (Fig 4A, 4B). According to the histopathological response criteria of the Japanese Breast Cancer Society, the pathological assessment of the therapeutic response was Grade 2[3]. We also recognized two swollen lymph nodes filled with mucus, but devoid of malignant cells.

Postoperatively, she received radiotherapy. She remains disease-free five months after the operation.

Discussion

Neoadjuvant chemotherapy has become standard therapy for patients with locally advanced or large operable breast cancers. This procedure makes breast-conserving surgery possible. In this report, we present a case of mucinous carcinoma, demonstrating a Grade 2 pathological response to neoadjuvant chemotherapy, despite no clinical response.

The reported incidence of mucinous carcino-

Fig 4. A: Despite widespread mucus in the primary breast tumor, microscopic analysis could recognize only a few viable malignant cells. The majority of these tumor cells were necrotic (hematoxylin and eosin [H&E] stain, original magnification, ×40), B: Viable malignant cells (H&E stain, original magnification, ×200).

ma has varied from 1% to 6% of all breast malignancies. Mucinous carcinoma has a better prognosis than infiltrating ductal carcinomas[4-6]. Komenaka *et al.* reported that the number of involved axillary lymph nodes was the only significant predictor of death from disease; the size of the lesion was not a significant prognostic factor in mucinous carcinoma, because the mucin comprised the majority of the tumor volume[5]. Pure mucinous carcinoma of the breast is suitable for breast-conserving therapy, even for large tumors of up to 5 cm in diameter, because these tumors have a low incidence of extensive intraductal spreading[6]. There have not been, however, any reports detailing the typical responses to chemotherapy or neoadjuvant chemotherapy for mucinous carcinoma of the breast. Mucinous carcinomas tend to be identified early, when the tumors are small in size and neoadjuvant chemotherapy is often unnecessary. According to multiple studies, tumors with aggressive biological markers, such as high histological grade, overexpression of HER-2, reactivity for p-53, and negative hormone receptor status, exhibited better pathological responses[7-9]. In mucinous carcinomas, estrogen and progesterone receptor positivity have been reported in approximately 60-90% of the tumors, while HER2/neu oncoprotein overexpression and p53 protein accumulation are not normally seen. These biological features suggest that mucinous carcinomas may not respond well to neoadjuvant chemotherapy. Fortunately, this estimation did not fit this case; the negative hormone receptor status of this tumor may be associated with a good response to neoadjuvant chemotherapy.

Categorization of the clinical response to chemotherapy depends on an accurate measurement of residual tumor size, but is complicated by variable histopathologic changes that can occur within the tumor bed. The remaining tumorous lesions may be related to chemotherapy-induced fibrosis, tumor necrosis, or fibrocystic changes. These secondary processes can result in clinical and macroscopic overestimation of the residual tumor size[10, 11]. Rajan *et al.* reported that chemotherapy in some tumors can dramatically reduce cellularity, but only minimally affects the overall tumor size[12]. In this case, chemotherapy was profoundly effective against the tumor cells themselves, but the large amounts of extacellular mucus were not sensitive to chemotherapy; thus, the remaining mucus made up a significant portion of the residual tumor. This phenomenon resulted in a discordance between the residual tumor size and the effectiveness of chemotherapy. Meanwhile, we observed five patients with pure type mucinous carcinoma that received neoadjuvant chemotherapy at our hospital (Table 1). The pathological assessments of the therapeutic responses of these tumors were Grade 1a (two cases), Grade 1b (two cases) and Grade 2 (this case) according to the percentage of necrotic malignant cells. Interestingly, in the two Grade 1b cases, approximately two-thirds of the tumor cells were necrotic, but large amounts of mucus remained. Due to the small number and varied responses, we could not

Table 1. Pure Type Mucinous Carcinoma of the Breast Receiving Neoadjuvant Chemotherapy

case	age	tumor size (cm)	regimen	tumor size (cm) postchemotherapy	clinical response	pathological response	ER	PgR
1	31	7	AT	4.9	PR	1a	−	−
2	39	3.5	AT	3.5	NC	1a	++	+
3	61	6.5	AC→PTX	3.5	PR	1b	++	+/−
4	53	1.3	AT→PTX	0.5	PR	1b	+	+/−
this case	30	5	CEF→PTX	5	NC	2	−	−

AT: adriamycin + docetaxel, AC: adriamycin + cyclophosphamide, PTX: paclitaxel, CEF: cyclophosphamide + epirubicin + 5FU

recognize a general trend in the responses to chemotherapy. These characteristic findings upon pathological examination, however, indicated that mucinous carcinomas may not be reduced in size even when the tumor cells are sensitive to chemotherapy.

In conclusion, discordance between residual tumor size and the effectiveness of chemotherapy may be observed in mucinous carcinoma. More detailed studies are required to establish the indications for chemotherapy and to evaluate therapeutic responses in patients with mucinous carcinoma.

References

1) Akashi-Tanaka S, Fukutomi T, Watanabe T, *et al*: Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. *Int J Cancer (Radiat Oncol Invest)* 96:66-73, 2001.
2) Akashi-Tanaka S, Fukuotmi T, Sato N, *et al*: The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. *Ann Surg* 239:238-243, 2004.
3) The Japanese Breast Cancer Society: General rules for clinical and pathological recording of breast cancer, 14th ed. Kanehara, Tokyo, 2000.
4) Andre S, Cunha F, Bernardo M, *et al*: Mucinous carcinoma of the breast: a pathological study of 82 cases. *J Surg Oncol* 58:162-167, 1995.
5) Ian K. Komenaka, Mahmoud B. El-Tamer, *et al*: Pure mucinous carcinoma of the breast. *Am J Surg* 187:528-532, 2004.
6) Anan K, Mitsuyama S, Tanaka K, *et al*: Pathological features of mucinous carcinoma of the breast are favorable for breast-conserving therapy. *EJSO* 27:459-463, 2001.
7) Henry M. Kuerer, Lisa A. Newman, Terry L. Smith, *et al*: Clinical course of breast cancer patients with complete pathologic primary tumor and lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* 17:460-469, 1999.
8) AH Honkoop, PJ van Diest, JS de Jong, *et al*: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. *British J Cancer* 77:621-626, 1998.
9) Frederique Penault-llorca, Anne Cayre, Florence Bouchet Mishellany, *et al*: Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. *Int J Oncol* 22:1319-1325, 2003.
10) Nakamura T, Fukutomi T, Tsuda H, *et al*: Changes in findings of mammography, ultrasonography and contrast-enhanced computed tomography of three histological complete responders with primary breast cancer before and after neoadjuvant chemotherapy: case reports. *Jpn J Clin Oncol* 30:453-457, 2000.
11) Edwin R. Fisher, Jiping Wang, John Bryant, *et al*: Pathobiology of preoparative chemotherapy. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18. *Cancer* 95:681-694, 2002.
12) Radhika Rajan, Anna Poniecka, Terry L. Smith, *et al*: Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. *Cancer* 100:1365-1373, 2004.

講座

術前化学療法後のセンチネルリンパ節生検

木下貴之[*1]　福富隆志[*1]　関　邦彦[*2]

Sentinel Lymph Node Biopsy for Breast Cancer Patients after Neoadjuvant Chemotherapy：Kinoshita T[*1], Fukutomi T[*2], Seki K[*3] ([*1,2]Surgical Oncology Division, [*3]Department of Pathology, National Cancer Center)

Despite the increasing use of both sentinel node biopsy and neoadjuvant chemotherapy in patients with operable breast cancer, there is still limited information on the feasibility and accuracy of sentinel node biopsy following neoadjuvant chemotherapy. So, the feasibility and accuracy of sentinel lymph node (SLN) biopsy for breast cancer patients with clinically node negative after neoadjuvant chemotherapy (NAC) has been investigated under the administration of a radiocolloid imaging agent injected intradermally over a tumor. Also, conditions which may affect SLN biopsy detection and false-negative rates with respect to clinical tumor response and clinical nodal status before NAC were also analyzed.

Our results show that SLN identification rate and false-negative rate after NAC are similar to those in nonneoadjuvant studies.

Key words：Breast cancer patients, After neoadjuvant chemotherapy, Sentinel node biopsy
Jpn J Breast Cancer 21(2)：135～139, 2006

はじめに

近年，センチネルリンパ節生検による腋窩郭清の省略と術前化学療法の併用により乳癌の外科治療は急速に縮小化の方向に進んでいる．センチネルリンパ節生検は，1990年代に始まり，従来の色素法にRIを用いたガンマプローブ法を組み合わせるなどの技術的改良と外科医自身の学習効果により，その成績も90%を超える同定率と5～10%の偽陰性率の達成が可能になってきている[1]．海外における69の施設と10,000人以上の患者を対象とした早期乳癌に対するセンチネルリンパ節生検のメタアナリシスの結果は，全体の同定率が90%以上で偽陰性率も8.4%と報告されている[2]．センチネルリンパ節生検の結果，腋窩郭清の省略が可能になった患者は，腋窩郭清を施行された患者と比較して術後合併症の頻度が低く，患手のむくみ，痺れ，運動障害などが軽度でQOLもより良好であると考えられる[1]．海外におけるセンチネルリンパ節生検の比較試験の長期的な成績が待たれるが，本邦においても多くの施設が既にセンチネルリンパ節生検の安全性試験を終了し実地医療へと移行しているものと考えられる．

一方，術前化学療法の導入により多くの症例でダウンステージ効果により乳房温存療法が可能になってきた．術前化学療法は従来，病期IIIB以上のいわゆる局所進行癌を対象に非切除例を切除可能にする目的で実施されてきたが，近年は病期IIAからIIIAの症例も術前化学療法の対象とし，原発巣が巣縮小した結果，多くの症例で乳房温存療法が可能となっている．これらの効果は，原発巣ばかりではなく当然，腋窩リンパ節転移巣にも確認されている．アンスラサイクリン系を含む術前化学療法では，腋窩リンパ節転移を約30%減じ[3]，さらにタキサン系を加えたレジメンでは約40%減ずると報告されている[4,5]．当院

*1 国立がんセンター中央病院外科
*2 国立がんセンター中央病院病理診断部

では1998年から2005年まで約360例の乳癌症例に術前化学療法を実施してきた．術前化学療法の原発巣における効果は，約85%以上の症例がPR以上であった．約25%の症例は原発巣がCRとなったが，これらの症例の腋窩リンパ節転移陽性率は25%で，早期乳癌のそれとほぼ同程度まで低下していることが確認された．このような術前化学療法が著効した症例に対して早期乳癌と同様にセンチネルリンパ節生検を実施し，腋窩郭清を省略することが可能かどうかを明らかにすることは非常に重要な課題である．

1．術前化学療法後のセンチネルリンパ節生検における問題点

術前化学療法後のセンチネルリンパ節生検に関してはいまだ十分なエビデンスは得られていない．これまでの報告例はいずれも単一施設で少数例の結果であり大規模な臨床試験は行われていない．早期乳癌症例に対するセンチネルリンパ節生検と比較すると，術前化学療法後の症例の問題点は，①腫瘍径の大きな症例が対象になる，②腋窩リンパ節転移の存在する，または存在した症例がより多く含まれる，③術前化学療法が腫瘍－リンパ管－リンパ節の流れに影響を与える可能性がある，④術前化学療法は転移陽性であったセンチネルリンパ節とノンセンチネルリンパ節に同程度の効果があるのか？⑤術前化学療法後のn0の意義がまだ明らかになっていない，などが挙げられる．これらの要因が術前化学療法のセンチネルリンパ節生検の妥当性を検証するうえで問題点となってきた．

1）海外での成績

術前化学療法後のセンチネルリンパ節生検のこれまで報告されてきた単一施設の成績を表1にまとめた[6~13]．症例数は15例から51例といずれも少数例での報告となっている．腫瘍径は平均で3.3 cmから5.5cmで，T1からT4まで対象とし，また，リンパ節転移が認められる症例も含めた試験も報告されている．これらのセンチネルリンパ節の同定率は84%から93%程度で，早期乳癌の成績よりやや低い程度である．偽陰性率は，0%から33%とばらつきを認める．これら7施設の報告をまとめると全体としての同定率は88.7%で，偽陰性率は5.3%である．ただし，偽陰性率に関してはNasonらの15例での33%という報告と少数例を対象にした0%という報告を除けば10%～15%程度という成績が臨床的にも妥当なのではないかと推測する．

術前化学療法後のセンチネルリンパ節生検のこれまで報告されてきた多施設の成績を表2にまとめた[14~17]．MamounasらはNational Surgical Adjuvant Breast and Bowel Project randomized trial (NSABP B-27) のAC4サイクルにdocetaxelを加えた術前化学療法後にセンチネルリンパ節生検が試みられた428例の成績を報告している[14]．試験が多施設にわたるためセンチネルリンパ節生検手技は，まちまちであるが全体としての同定率は85%，偽陰性率は11%という結果である．その他の3つの多施設からの報告も同定率が90%前後，偽陰性率が10%前後と早期乳癌に対するセンチネルリンパ節生検の成績と遜色のない結果が報告されている．

また，これらの結果からわかることは，術前化学療法後にセンチネルリンパ節生検を行う際には，色

表1　術前化学療法後センチネルリンパ節生検－単施設の成績－

	症例数	病期	平均腫瘍径(cm)	同定数(%)	偽陰性数(%)
Breslin et al.,2000[6]	51	II or III	5.0	43(84.3)	3(12)
Miller et al.,2002[7]	35	T1-3N0	3.5	30(86.0)	0(0)
Stearns et al.,2000[8]	34	T3-4, any N	5.0	29(85.0)	3(14)
Haid et al.,2001[9]	33	T1-3, any N	3.3	29(88.0)	0(0)
Julian et al.,2002[10]	31	I or II	NS	29(93.5)	0(0)
Tafra et al.,2001[11]	29	Any T, N0	NS	27(93.0)	0(0)
Nason et al.,2000[12]	15	T2-4, N0	NS	13(87.0)	3(33)
Shimazu et al.,2004[13]	47	II or III	4.5	44(93.6)	4(12)
Kinoshita et al., 2005	88	T2-4, any N	4.9	81(92.0)	3(9)

表2　術前化学療法後センチネルリンパ節生検－多施設の成績－

	症例数	手技(色素/RI)	同定率(%)	偽陰性率(%)
Mamounas et al[14]	428	Blue dye	78	14
(NSABP B-27)		Radiocolloid	89	5
		Combination	88	9
		All techniques	85	11
Krag et al[15]	443	Radiocolloid	93	11
Tafra et al[16]	529	Combination	87	13
McMaster et al[17]	806	Blue dye or Radiocolloid	86	12
		Combination	90	6
		All Techniques	88	7

表3　患者背景

	症例数
平均年齢(歳)	50.2 (27-77)
平均腫瘍径 (cm)*	4.91 (2.7-12)
T分類*	
T2	54 (61%)
T3	28 (32%)
T4	6 (7%)
N分類*	
N0	46 (52%)
N1	34 (39%)
N2	8 (9%)
組織型	
浸潤性乳管癌	86 (98%)
浸潤性小葉癌	2 (2%)
術前化学療法	
FEC plus paclitaxel	85 (97%)
paclitaxel alone	3 (3%)
臨床的腫瘍効果	
CR	45 (51%)
PR	35 (40%)
NC	8 (9%)
病理組織学的腫瘍効果	
pCR	34 (39%)
pINV	54 (61%)
リンパ節転移	
陰性	38 (43%)
陽性	50 (57%)

*化学療法前
pCR＝pathological complete response；pINV＝pathological invasive

素法単独より色素法にRI法を併用した方が成績がよいということである．

2) 国立がんセンターの成績

当院では，早期乳癌に対するセンチネルリンパ節生検のfeasibility studyを終了後，2003年7月より術前化学療法後の乳癌症例に対するセンチネルリンパ節生検のfeasibility studyを開始し，その成績を報告してきた．本試験は単一の外科医，手技により実施された．

腫瘍径3 cm以上あるいは腋窩リンパ節転移を認める乳癌症例を対象に術前化学療法として，①FEC/ACを4サイクル，②weekly paclitaxelを12サイクルを組み合わせたものを原則とし，高齢者にのみ②だ

表4　国立がんセンターにおけるセンチネルリンパ節生検の成績

	センチネルリンパ節の転移	非センチネルリンパ節の転移
	陽性	陰性
陽性	16	14
陰性	3	48

False negative rate, 9.1%; overall accuracy, 96.3%; negative predictive value, 94.1%; positive predictive value, 100%

け実施した．術前化学療法後に原発巣がPR以上の効果を示し，かつ，治療後腋窩リンパ節転移が陰性であった88例をセンチネルリンパ節生検の対象とした．これらの平均腫瘍径は4.9cm（2.5cm～12.0cm）で，T4が6例，治療前に明らかにリンパ節転移を認めた42例も対象となっている（表3）．センチネルリンパ節生検は，色素－RI法を用いたものが80例で，色素法単独が8例となっている．結果として，センチネルリンパ節が同定できた症例は80例で，同定率は92%となる．これらの症例のセンチネルリンパ節とノンセンチネルリンパ節の転移の有無をまとめたものを表4に示す．センチネルリンパ節に転移を認めず，ノンセンチネルリンパ節に転移を認めたものは3例で偽陰性率は9%であり，全体として96%の症例においてセンチネルリンパ節が腋窩リンパ節全体の状況を正確に反映していることが証明された．臨床的諸因子とセンチネルリンパ節の同定率との関連を検討したが，治療前のリンパ節転移の有無，臨床的治療効果，病理組織学的治療効果は関連せず，唯一，T4d（炎症性乳癌）症例のみがセンチネルリンパ節の同定を困難にしていることが明らかとなった．一方，センチネルリンパ節が同定できた症例中，偽陰性になった症例は3例のみであったため，術前化学療法も含めてこれらに影響を与える因子は明らかではなかった．

まとめ

当院での術前化学療法後センチネルリンパ節生検の結果から，炎症性乳癌以外の術前化学療法が著効した症例において，センチネルリンパ節生検は十分に安全に実施できると結論づけられた．同定率は92%，偽陰性率は9%で，早期乳癌における成績と遜色のないものとなった．海外における最近の報告や多施設からの報告は，当院の結果を支持するものである．一方，2005年度にJournal of Clinical Oncology（JCO）に発表されたAmerican Society of Clinical Oncology（ASCO）のガイドラインでは，Preoperative systemic therapy後のセンチネルリンパ節生検に関して，①技術的には安全に実施することはできる，②Preoperative systemic therapy後のn0の意義が明らかでない，③これらの症例では，正確な腋窩リンパ節の転移状況の把握が治療方針を決める際に重要であること，④エビデンスが十分でない，ことより推奨されていない．正確な腋窩リンパ節の情報を得るという目的からするとセンチネルリンパ節生検をPreoperative systemic therapyの前に施行し，Preoperative systemic therapy後に実施する場合でもN0症例に限られるべきだと強調している[18]．

当院での成績から，強力で安定した化学療法の後，色素－RI法を用い熟練した手技のもとにセンチネルリンパ節生検は，安全に実施できることが確認された．術前化学療法が著効した乳癌症例では，腋窩リンパ節陽性率が25%程度になることから術前化学療法後にセンチネルリンパ節生検を実施することに意義があるものと考える．ただし，本対象が進行癌であるということを十分に認識し，腫瘍内科医，病理医，放射線診断医との連携のもとに，慎重に適応を決めて本手技を修練，実施することが望まれる．

文　献

1）Veronesi U, Pagenelli G, Viale G, et al：A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. *N Engl J Med* 349：546-553, 2003

2) Kim T, Agboola O, Lyman GH, et al : Lymphatic mapping and sentinel lymph node sampling in breast cancer : meta-analysis. *Proc Am Soc Clin Oncol* 21 : 36a, 2002
3) Fisher B, Brown A, Mamounas E, et al : Effect of preoperative chemotherapy of local-regional disease in women with operable breast cancer : findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol* 15 : 2483-2493, 1997
4) Mamounaus E, Brown A, Smith R, et al : Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer : update results from NSABP B-27. *Proc Am Soc Clin Oncol* 21 : 36a, 2002
5) Gianni L, Baselga H, Eiermann W, et al : First report of European Cooperative Trial in operable breast cancer (ECTO) : effect of primary systemic therapy (PST) onlocal-regional disease. *Proc Am Soc Clin Oncol* 21 : 34 a, 2002
6) Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy in accurate after neoadjuvant chemotherapy for breast cancer. *J Clin Oncol* 18 : 3480-3486, 2000
7) Miller AR, Thompson VE, Yeh IT, et al : Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. *Ann Surg Oncol* 9 : 243-247, 2002
8) Stearns V, Ewing CA, Slake R, et al : Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliable represent the axilla except for inflammatory breast cancer. *Ann Surg Oncol* 9 : 235-242, 2000
9) Haid A, Tausch C, Lang A, et al : Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast cancer? *Cancer* 92 : 1080-1084, 2001
10) Julian TB, Dusi D, Wolmark N : Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. *Am J Surg* 184 : 315-317, 2002
11) Tafra L, Verbanac KM, Lannin DR : Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. *Am J Surg* 182 : 312-315, 2001
12) Nason KS, Anderson BO, Byrd DR, et al : Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. *Cancer* 89 : 2187-2194, 2000
13) Shimazu K, Tamaki Y, Taguchi T, et al : Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. *Cancer* 100 : 2555-2561, 2004
14) Mamounas E, Brown A, Anderson S, et al : Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer : Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 23 : 2694-2702, 2005
15) Krag D, Weavre D, Ashikaga T, et al : The sentinel node in breast cancer－A multicenter validation study. *N Engl J Med* 339 : 941-946, 1998
16) Tafra L, Lannin DR, Swason MS, et al : Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloidal and isosulfan blue dye. *Ann Surg* 223 : 51-59, 2001
17) McMaster KM, Tuttle TM, Carison DJ, et al : Sentinel lymph node biopsy for breast cancer : A suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique in used. *J Clin Oncol* 18 : 2560-2566, 2000
18) Lyman GH, Giuliano MR, Somerfield MR, et al : American Society of Clinical Oncology guideline recommendation for sentinel lymph node biopsy in early-stage breast cancer. *J Clin Oncol* 23 : 7703-7720, 2005

Ipsilateral Breast Tumor Recurrence (IBTR) after Breast-Conserving Treatment for Early Breast Cancer

Risk Factors and Impact on Distant Metastases

Yoshifumi Komoike, M.D.[1]
Futoshi Akiyama, M.D.[2]
Yuichi Iino, M.D.[3]
Tadashi Ikeda, M.D.[4]
Sadako Akashi-Tanaka, M.D.[5]
Shozo Ohsumi, M.D.[6]
Mikihiro Kusama, M.D.[7]
Muneaki Sano, M.D.[8]
Eisei Shin, M.D.[9]
Kimito Suemasu, M.D.[10]
Hiroshi Sonoo, M.D.[11]
Tetsuya Taguchi, M.D.[12]
Tsunehiro Nishi, M.D.[13]
Reiki Nishimura, M.D.[14]
Shunsuke Haga, M.D.[15]
Keiichi Mise, M.D.[16]
Takayuki Kinoshita, M.D.[17]
Shigeru Murakami, M.D.[18]
Masataka Yoshimoto, M.D.[19]
Hideaki Tsukuma, M.D.[20]
Hideo Inaji, M.D.[1]

BACKGROUND. The clinical features of ipsilateral breast tumor recurrence (IBTR) after breast conserving therapy (BCT) for early stage breast cancer were analyzed from long-term follow-up of BCT in Japan. The purpose of this study was to clarify risk factors of IBTR and the impact of IBTR on development of distant metastases in this ethnic group.

METHODS. Patients (N = 1901)with unilateral breast cancer ≤ 3 cm in diameter who underwent BCT at 18 Japanese major breast cancer treatment institutes from 1986 to 1993 were registered in this study. Survival rates, the incidences of IBTR and distant metastases, and annual rates of IBTR and distant metastases after primary operation were calculated by the Kaplan–Meier method. A Cox proportional hazards model was used to estimate the risks of IBTR and distant metastases. A Cox model was also used to estimate the risks of distant metastases after IBTR in the group of IBTR.

RESULTS. At a median follow-up time of 107 months, the 10-year overall and disease-free survival rates were 83.9% and 77.8%, respectively. The 10-year cumulative rates of IBTR were 8.5% in the patients with postoperative irradiation and 17.2% in the patients without irradiation. The 10-year cumulative distant metastasis rate was 10.9%. On multivariate analysis, young age, positive surgical margin, and omission of radiation therapy were significant predictors of IBTR. In addition, IBTR significantly correlated with subsequent distant metastases (hazard ratio, 3.93; 95% confidence interval, 2.676–5.771; $P < 0.0001$). Among patients who

[1] Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.

[2] Department of Breast Pathology, Cancer Institute Hospital, Tokyo, Japan.

[3] Department of Emergency and Critical Care Medicine, Gunma University Faculty of Medicine, Gunma, Japan.

[4] Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

[5] Division of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan.

[6] Department of Surgery, National Shikoku Cancer Center, Ehime, Japan.

[7] Third Department of Surgery, Tokyo Medical University, Tokyo, Japan.

[8] Department of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.

[9] Department of Surgery, National Osaka Hospital, Osaka, Japan.

[10] Department of Surgery, Saitama Cancer Center, Saitama, Japan.

[11] Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan.

[12] Department of Surgical Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.

[13] Department of Surgery, Mitsui Memorial Hospital, Tokyo, Japan.

[14] Department of Surgery, Kumamoto City Hospital, Kumamoto, Japan.

[15] Department of Surgery, Tokyo Women's Medical University Daini Hospital, Toyko, Japan.

[16] Kodama Clinic, Fukuoka, Japan.

[17] Department of Surgery, National Tokyo Medical Center Hospital, Tokyo, Japan.

[18] Department of Breast Oncology, National Kyushu Cancer Center 1, Kyoto, Japan.

[19] Department of Breast Surgery, Cancer Institute Hospital, Tokyo, Japan.

[20] Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.

Supported by a Grant-in-Aid for research of cancer treatment from the Ministry of Health, Labour and Welfare of Japan (No.13-9).

Address for reprints: Yoshifumi Komoike, Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan; Fax: (011) 81-6-6981-8055; E-mail: komoike-yo@mc.pref.osaka.jp

Received June 29, 2004; revision received June 16, 2005; accepted July 19, 2005.

DOI 10.1002/cncr.21551
Published online 6 December 2005 in Wiley InterScience (www.interscience.wiley.com).

developed IBTR, initial lymph node metastases and short interval to IBTR were significant risk factors for subsequent distant metastasis.

CONCLUSIONS. Young age, positive surgical margin, and omission of radiation therapy seemed to be important factors in relation to local control. The authors' results also indicated that IBTR is significantly associated with subsequent distant metastasis. Patients with positive nodal status at primary operation or with short interval from primary operation to IBTR are at especially high risk of distant metastasis. It remains unclear, however, whether IBTR is an indicator or a cause of subsequent distant metastases. *Cancer* 2006;106:35–41.

KEYWORDS: breast cancer, breast-conserving treatment, ipsilateral breast tumor recurrence, distant metastases.

A long time has passed since breast-conserving therapy (BCT) became the standard treatment modality for early stage breast cancers.[1–2] The increasing number of patients treated with BCT resulted in a corresponding increase of ipsilateral breast tumor recurrence (IBTR). The main concern for both physicians and patients is, therefore, the risk of IBTR in the preserved breast.

Postoperative irradiation to the remaining breast has significantly reduced the incidence of IBTR.[1–5] The results of the recent National Surgical Adjuvant Bowel and Breast Project (NSABP) B-21, showed that radiation therapy was so effective that it would even benefit early breast cancers at minimal risk for IBTR.[6] Therefore, postoperative irradiation was thought to be an important part of standard procedure for BCT.

In addition to radiation therapy, some factors were reported to have an influence on IBTR. For example, young women were generally thought to have a higher frequency of local recurrence.[7–11] Kroman et al. recently reported a relation between young age and increasing risk of IBTR, from a study of BCT with over 2000 patients.[12] The European Organization for Research and Treatment of Cancer (EORTC) trial also confirmed the impact of age.[13]

The presence or absence of cancer cells at the resection margin, and their quantity, are also major factors affecting IBTR.[14–19] Park et al. reported that the 8-year accrued rate of IBTR was 7% in patients with negative and close margins, 14% in those with focally positive margins, and 27% in those with extensively positive margins.[14] Although the definitions of positive margin are obscure, the importance of pathologic margin status in relation to the risk of IBTR has been shown.

Many studies have shown that IBTR is associated with subsequent distant metastases (DM) and worse survival.[20–28] Whether IBTR is an indicator or a cause of subsequent DM is debatable.[26,29–33] It has been proposed that IBTR is not the cause but is simply a significant indicator of subsequent DM. Other groups have recently suggested that IBTR may be a cause of DM.[32,34,35]

In the current study, we summarized the long-term follow-up results of BCT for Japanese women with breast cancer, and we focused on IBTR, particularly its incidence, risk factors, and predictive significance for subsequent DM. In Japan, BCT was adopted later than in western countries. Therefore, there are few studies summarizing the results of BCT for Japanese women.[36,37] This is the first long-term report of large-scale results of BCT in this ethnic group.

MATERIALS AND METHODS

Included in this study were 1901 patients with unilateral breast cancer ≤ 3 cm in diameter who underwent BCT at 18 major institutes from 1986 to 1993. Patients who had received primary systemic therapy, and those with past history of breast cancer, were excluded. Postoperative irradiation or adjuvant therapy were not exclusion criteria. The surgical procedure consisted of wide excision or quadrantectomy plus axillary lymph node dissection.

Questionnaire forms were sent to the members of this study in November 2001 to collect clinical patient data. The questionnaire asked for data as follows: age at primary operation, menopausal status, date of primary operation, initial tumor size by palpation, histologic type, pathologic lymph node status, histologic margin status, lymphovascular invasion, nuclear grade, extensive intraductal component (EIC), estrogen receptor status (ER), progesterone receptor status (PgR), adjuvant endocrine therapy, adjuvant chemotherapy, postoperative irradiation, boost radiation, date of IBTR, method of salvage operation, systemic therapy after IBTR, secondary local recurrence and its date, distant metastases, date of distant metastases, contralateral breast cancer, death, cause of death, and date of death or last visit. Serial sections of resected specimens were meticulously examined at all institu-

tions. Margins ≤ 5 mm from the cut edge of the specimen were usually regarded as positive margins. Measurement methods and cutoff levels of the hormone receptors were not standardized, and they varied between institutions.

IBTR was defined as all events which occurred in the remaining breast after BCT. No distinction was made between recurrence because of residual cancer cells or because of new primary cancer.

Local-free, disease-free, distant disease-free, and overall survival rates were calculated using the Kaplan–Meier method. The statistical differences of local, distant, disease-free rates, and overall survival were proved using a log-rank test for univariate analysis. Multivariate analyses for local free and distant disease-free rates were performed using the Cox proportional hazards model. In univariate and multivariate analysis, age was dealt with as a serial variable and was not categorized at a certain point, such as ≤ 35 years or older. All statistical analyses were performed with Stat View 5.0 software (SAS Institute, Cary, NC).

RESULTS

Systemic Recurrence and IBTR

There were 1901 patients available for analysis of survival and recurrence rates. The median follow-up period was 107 months(range, 2–184 mos). Patient characteristics are shown in Table 1. There were 172 patients who developed IBTR, and 179 patients had recurrences in distant organs or regional lymph nodes. During follow-up, 182 patients died; of these, 128 patients died of their breast cancers. The 10-year overall and cause-specific survival rates were 83.9% and 92.2%, respectively. The 10-year distant disease-free survival was 77.8%. The 10-year cumulative rate of IBTR was 9.6% (8.5% in the group with postoperative irradiation and 17.2% in the group without RT). There was a significant difference between these two groups ($P < 0.0001$).

Risk Factors for IBTR

Factors influencing IBTR are shown in Table 2. In a univariate analysis, younger age at primary operation, tumor size, positive margin status, high nuclear grade, EIC, PgR, omission of endocrine therapy, and omission of postoperative irradiation were significantly associated with IBTR. Of these, younger age, positive margin status, and omission of postoperative irradiation were independently associated with IBTR on a multivariate Cox proportional hazards model analysis.

Time Course of IBTR and Distant Metastasis

The annual rate and cumulative incidence of IBTR after primary operation is shown in Figure 1. The peak of IBTR was seen at 3 to 4 years after primary operation, and the annual rate decreased gradually thereafter. Figure 2 shows the clinical outcome of patients with and without IBTR. Patients who developed IBTR had a significantly greater risk of developing DM ($P < 0.0001$).

TABLE 1
Patient Characteristics

Characteristic	No. of patients
Age, yrs	
Median	49
Range	21–89
≤ 35	135
> 36	1766
Clinical tumor size, cm	
Median	17
Range	0–30
Lymph node metastasis	
Positive	380
Negative	1476
Unknown	45
ER status	
Positive	779
Negative	482
Unknown	640
PgR status	
Positive	510
Negative	430
Unknown	961
Surgical margin	
Positive	263
Negative	1503
Uncertain	135

ER: estrogen receptor; PgR: progesterone receptor.

Risk Factors for Distant Metastasis

Both distant disease-free and overall survival rates were significantly lower in the IBTR group. To determine whether IBTR is related to DM and patient prognosis, we verified risk factors for DM. Univariate analysis showed that initial age, lymph node metastases, margin status, lymphovascular invasion, nuclear grade, EIC, PgR, and IBTR were all significantly correlated with DM (Table 3). In a multivariate analysis, IBTR was independently associated with DM as well as with lymph node metastases. The hazard ratio (HR) associated with distant metastasis was 3.93 (95% confidence interval [CI], 2.676–5.771) in IBTR, and 3.34 (95% CI, 2.365–4.724) in node-positive patients (Table 3).

Of 1901 patients, 172 developed IBTR, and 51 developed subsequent DM after IBTR; 27 of these patients developed distant metastases within 1 year after IBTR.

TABLE 2
Factors Influencing Ipsilateral Breast Tumor Recurrence (IBTR), Results of Univariate and Multivariate Analysis

Variable	Univariate analysis *P* value	Multivariate analysis HR	*P* value	95% CI
Age	< 0.0001	0.943	< 0.0001	0.917–0.970
Size	0.0257	1.017	0.2557	0.988–1.047
Histologic type				
DCIS/IDC/special	0.6053			
Lymph node metastasis				
+/−	0.141			
Surgical margin				
+/−	< 0.0001	2.849	0.0004	1.587–5.012
ly +/−	0.8768			
v +/−	0.5236			
Nuclear grade				
3/1, 2	0.0650			
EIC +/−	0.0106	1.422	0.1857	0.847–2.398
ER −/+	0.0493	0.696	0.1464	0.427–1.135
PgR −/+	0.0036			
Chemotherapy				
−/+	0.0878			
Endocrine therapy				
−/+	0.0180	1.543	0.0824	0.397–1.057
Radiation therapy				
−/+	< 0.0001	3.861	< 0.0001	0.155–0.433

HR: hazard ratio; CI: confidence interval; DCIS: ductal carcinoma in situ; IDC: invasive ductal carcinoma; Special: lobular carcinoma, medullary carcinoma, squamous cell carcinoma, etc.; ly: lymphatic invasion; v: vascular invasion; EIC: extensive intraductal component; ER: estrogen receptor; PgR: progesterone receptor.



FIGURE 1. Annual and cumulative rates of ipsilateral breast tumor recurrence (IBTR) after primary operation are represented. The bar graph shows annual rates of IBTR. It was 1 to 2% up to 7 years from primary operation. After that, the incidences decreased slightly, but they did not reach zero. The incidence was highest at 4 to 5 years after primary operation. The line graph shows cumulative incidence of IBTR. It was linear to 7 years and a little flattened thereafter.

Factors associated with distant metastases among patients who developed on IBTR were analyzed. Univariate analysis showed that nodal status, lymphovascular invasion, and period to IBTR were potential risk factors for DM. Initial nodal status and interval to IBTR were independent risk factors for DM by Cox proportional hazard model (Table 4). Annual rates of DM for primary operation in patients with or without IBTR were compared (Fig. 3). The incidences of DM in the group of patients with IBTR were higher than those in the group of patients without IBTR regardless of the time after operation. More interestingly, the annual rates of distant metastases in the group of patients with IBTR showed two



FIGURE 2. Distant-free survival after primary operation is shown according to local relapse. The distant-free survival curve shows that patients with IBTR are more likely to develop subsequent distant metastases. There was a statistically significant difference between the two groups ($P < 0.0001$). The actuarial distant-free survival rate at 10 years was 89.7% in the local control group and 70.3% in the IBTR group.

TABLE 3
Risk Factors for Distant Metastases After Breast Conserving Surgery, Results of Univariate and Multivariate Analysis

Variable	Univariate analysis HR	*P* value	Multivariate analysis HR	*P* value	95% CI
Age	0.979	0.004	0.99	< 0.30	0.978–1.008
Size	1.013	0.10			
Lymph node metastasis					
+/−	3.55	< 0.0001	3.34	< 0.0001	2.365–4.724
Surgical margin					
+/−	1.46	0.03	1.30	0.20	0.873–1.926
ly +/−	2.16	< 0.0001			
v +/−	1.98	0.002			
Nuclear grade					
3/1, 2	3.32	0.006			
EIC +/−	0.57	0.03			
ER −/+	0.79	0.16			
PgR −/+	0.64	0.01			
IBTR +/−	3.72	< 0.0001	3.93	< 0.0001	2.676–5.771

HR: hazard ratio; CI: confidence interval; ly: lymphatic invasion; v: vascular invasion; EIC: extensive intraductal component; ER: estrogen receptor; PgR: progesterone receptor; IBTR: ipsilateral breast tumor recurrence.

TABLE 4
Risk Factors for Subsequent Distant Metastases After IBTR, Results of Univariate and Multivariate Analysis

Variable	Univariate analysis *P* value	Multivariate analysis HR	*P* value	95% CI
Age	0.1724			
Size	0.5618			
Lymph node metastasis				
+/−	< 0.001	2.68	0.008	1.291–5.574
Surgical margin				
+/−	0.3113			
ly +/−	0.0161	1.21	0.599	0.888–2.506
v +/−	< 0.0001			
Nuclear grade				
3/1, 2	NE			
EIC +/−	0.2134			
ER −/+	0.4057			
PgR −/+	0.2230			
DFI	< 0.0001	0.99	0.008	0.999–1.000

HR: hazard ratio; CI: confidence interval; ly: lymphatic invasion; v: vascular invasion; EIC: extensive intraductal component; ER: estrogen receptor; PgR: progesterone receptor; DFI: disease free interval.



FIGURE 3. The time distribution of distant metastases after primary operation compares the local control group (LC) and IBTR group. In the group of patients without IBTR, the incidence of DM was high at 2 to 4 years after primary operation, and it gradually decreased thereafter. By contrast, in the group of patients with IBTR, the annual rates of distant metastases showed two peaks, 4 to 5 years and 12 to 13 years after primary operation. The proportion of DM after 9 years was remarkably high.

peaks, and the incidence of DM after 9 years was remarkably high. By contrast, in the group of patients without IBTR, the incidence of DM was high at 2–4 years after primary operation and subsequently decreased.

DISCUSSION

The current study was conducted to clarify the risk factors for IBTR, as well as the impact of IBTR on distant metastases in patients with early stage breast cancer treated with BCT. We first summarized the results of BCT cases in Japan with long-term follow-up. As previously reported,[36,37] the survival rates and local control rates of BCT in Japan were favorable. Risk factors of IBTR were younger age, positive margin status, and omission of postoperative irradiation. These results were consistent with previous reports.

The 10-year cumulative rates of IBTR were 8.5% and 17.2% in patients with and without radiation therapy, respectively. On a Cox proportional hazards model, postoperative irradiation decreased the risk of IBTR by about one-fourth (HR, 0.259, 95% CI, 0.214–0.431, $P < 0.0001$). This result is similar to the result of Early Breast Cancer Trialists' Collaborative Group (EBCTCG) metaanalysis.[38]

In the current study, positive surgical margins were also associated with an increased risk of IBTR as previously reported.[14–18] However, definitions of margin status are not standardized. Some researchers defined it only as "positive" or "negative".[16,20] Other studies have assessed surgical margin according to distance from the cut edge,[17] but these distances varied by < 1 mm, < 2mm, or < 10mm.[14,19,39] In the current study, the majority of close margins (≤ 5 mm from the cut edge of the specimen) were regarded as positive margins. Although judgment of margin status depends on each institution, meticulous histologic assessment was done in all institutions. (The removed specimens are examined by expert pathologists at each institute, by using 5 mm sections.)

The influence of young age on the risk of IBTR is striking. It has been supported by many previous studies.[7–11] Jobsen et al. reported that age < 40 years was the only significant predictor of IBTR for women treated with BCT with pathologic T1 tumors and negative lymph node status.[10] Harrold et al. showed a correlation with young age and IBTR by using a cut-point age of 40 years.[40] Freedman et al. also found age to be a risk factor of IBTR, but their cut-point age was 55 years.[9] Fourquet et al. categorized patients into 4 age groups (< 32, 32–45, 46–55, > 55).[7] In our series, age was analyzed as a serial variable. The results are that the younger the patient, the higher the risk of IBTR. It was noteworthy that younger age was a risk factor of IBTR regardless of age cut-point.

Our results also showed that IBTR was significantly correlated with DM, as shown by several other reports.[19–24] The HR was 3.93 by multivariate analysis. This ratio was very similar to that of NSABP B-06.[20] When compared with the relative risk (3.34) of lymph node metastasis for distant metastasis, IBTR has almost the same impact on DM.

One of the aims of this study was to clarify what type of IBTR is likely to develop subsequent DM. Univariate analysis showed that initial lymph node metastases,